Continuous Monitoring of Circadian Glycemic Patterns In Patients Receiving Prednisolone For COPD

Burt, Morton G.; Roberts, G. W.; Aguilar-Loza, Norma; Frith, Peter; Stranks, Stephen N

doi:10.1210/jc.2010-2729

Cited by 161 publications

(129 citation statements)

References 21 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…The latter two reports showed FPG was not increased by glucocorticoids. The different points of Rizza's study from the latter two reports are 1) Study subjects were healthy volunteers, and 2) Glucocorticoid treatment period was much shorter (24-h infusion) in healthy volunteers than in patients with chronic obstructive pulmonary disease or Cushing's syndrome [3,13,14].…”

Section: Discussionmentioning

confidence: 99%

“…Rizza et al showed that cortisol increased fasting glucose production and more insulin was required to reduce glucose production after cortisol infusion than saline by euglycemic hyperinsulinemic clamp studies on healthy volunteers [13]. On the other hand, synthetic glucocorticoids particularly increase postprandial PG, but not FPG, in patients with chronic obstructive pulmonary disease [14]. It has been reported that endogenous glucocorticoid excess in patients with Cushing's syndrome predominantly increases postprandial PG with FPG often in the normal range [3].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incompatibility between fasting and postprandial plasma glucose in patients with Cushing’s syndrome

et al. 2016

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Incompatibility between fasting and postprandial plasma glucose in patients with Cushing’s syndrome

et al. 2016

View full text Add to dashboard Cite

“…It is unknown what contribution this hypersensitive state may have had in exacerbating or predisposing to glucose intolerance following even a single prednisone dose. Furthermore, it has been reported that interstitial hyperglycaemia associated with prednisolone treatment is predominantly manifested in the afternoon and evening in patients receiving prednisolone treatment while undergoing continuous glucose monitoring (31). Accordingly, the OGTT was conducted during the mid-late afternoon.…”

Section: Discussionmentioning

confidence: 99%

Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals

Kauh

Mixson

Malice

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Use of glucocorticoids for anti-inflammatory efficacy is limited by their side effects. This study examined, in the same individuals, prednisone's acute, dose-dependent effects on inflammation as well as biomarkers of glucose regulation and bone homeostasis. Design: In this randomized, double-blind, parallel-design trial of healthy adults demonstrating cutaneous allergen-induced hypersensitivity, patients received placebo or prednisone 10, 25 or 60 mg daily for 7 days. Methods: Effects on peripheral white blood cell (WBC) count, ex vivo whole blood lipopolysaccharide (LPS)-stimulated TNF-a release and response to cutaneous allergen challenge were assessed concurrently with biomarkers for glucose tolerance and bone turnover. Results: Differential peripheral WBC counts changed significantly within hours of prednisone administration. Ex vivo, LPS-stimulated TNF-a was significantly reduced by all prednisone doses on days 1 and 7. The late phase cutaneous allergen reaction was significantly reduced with prednisone 60 mg vs placebo on days 1 and 7. Oral glucose tolerance tests revealed significant increases in glycaemic excursion on days 1 and 7, whereas increases in insulin and C-peptide excursions were more notable on day 7 with all doses of prednisone. The bone formation markers osteocalcin, and procollagen I N-and C-terminal peptides decreased significantly on days 1 and 7 vs placebo. Conclusions: In healthy young adults after single doses as low as 10 mg, prednisone treatment has significant effects on glucose tolerance and bone formation markers within hours of treatment, in parallel with anti-inflammatory effects.

show abstract

“…The role of b 2 -agonists and oral steroid therapy has already been demonstrated [132]. SUISSA et al [133] confirmed that high-dose inhaled corticosteroids are a risk factor for the development or poor control of diabetes.…”

Section: Impact Of Treatmentsmentioning

confidence: 96%

Comorbidities of COPD

Cavaillès¹,

Brinchault-Rabin²,

Dixmier³

et al. 2013

European Respiratory Review

410

285

View full text Add to dashboard Cite

By 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality. Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco smoking is a common risk factor for many comorbidities, including coronary heart disease, heart failure and lung cancer. Comorbidities such as pulmonary artery disease and malnutrition are directly caused by COPD, whereas others, such as systemic venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic syndrome, diabetes, sleep disturbance and anaemia, have no evident physiopathological relationship with COPD. The common ground between most of these extrapulmonary manifestations is chronic systemic inflammation.All of these diseases potentiate the morbidity of COPD, leading to increased hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and need to be evaluated and treated adequately. @ERSpublications Extrapulmonary comorbidities are common in COPD and influence prognosis; we propose an exhaustive comorbidities review

show abstract

Continuous Monitoring of Circadian Glycemic Patterns In Patients Receiving Prednisolone For COPD

Abstract: Prednisolone predominantly causes hyperglycemia in the afternoon and evening. Treatment of prednisolone-induced hyperglycemia should be targeted at this time period.

Cited by 161 publications

References 21 publications

Incompatibility between fasting and postprandial plasma glucose in patients with Cushing’s syndrome

Incompatibility between fasting and postprandial plasma glucose in patients with Cushing’s syndrome

Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals

Comorbidities of COPD

Contact Info

Product

Resources

About

Continuous Monitoring of Circadian Glycemic Patterns In Patients Receiving Prednisolone For COPD

Abstract: Prednisolone predominantly causes hyperglycemia in the afternoon and evening. Treatment of prednisolone-induced hyperglycemia should be targeted at this time period.

Cited by 161 publications

References 21 publications

Incompatibility between fasting and postprandial plasma glucose in patients with Cushing&rsquo;s syndrome

Incompatibility between fasting and postprandial plasma glucose in patients with Cushing&rsquo;s syndrome

Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals

Comorbidities of COPD

Contact Info

Product

Resources

About

Incompatibility between fasting and postprandial plasma glucose in patients with Cushing’s syndrome

Incompatibility between fasting and postprandial plasma glucose in patients with Cushing’s syndrome